07:40 AM EDT, 09/17/2024 (MT Newswires) -- Senseonics ( SENS ) said Tuesday the US Food and Drug Administration has cleared the Eversense 365 continuous glucose monitoring, or CGM, system for people with Type 1 and Type 2 diabetes aged 18 years and older.

Eversense 365 provides one year of use, the company said.

Senseonics ( SENS ) said it plans to launch Eversense 365 in the US in early Q4.